1. Pathophysiology and clinical meaning of small resistance artery remodeling

   • Enrico Agabiti Rosei
   • Damiano Rizzoni

   Invited Commentary Pages: 79 - 80

2. Web alert

   News Pages: 81 - 82

3. The metabolic effects of angiotensin-receptor blockers

   • Michael L. Tuck
   • Dalila B. Corry

   Clinical Trials Report Pages: 85 - 87

4. Metabolic syndrome and endothelial dysfunction

   • Alessia Fornoni
   • Leopoldo Raij

   OriginalPaper Pages: 88 - 95

5. Advanced-glycation end products in insulin-resistant states

   • Georgia Soldatos
   • Mark E. Cooper
   • Karin A. M. Jandeleit-Dahm

   OriginalPaper Pages: 96 - 102

6. The metabolic syndrome in the Asian population

   • Hiromi Rakugi
   • Toshio Ogihara

   OriginalPaper Pages: 103 - 109

7. Metabolic syndrome therapy: Prevention of vascular injury by antidiabetic agents

   • Ligia J. Dominguez
   • James R. Sowers

   OriginalPaper Pages: 110 - 116

8. ACE inhibitors in patients with vascular disease: Should the peace trial change medical practice?

   • Robert M. Carey

   Clinical Trials Report Pages: 119 - 120

9. BENEDICT in the treatment of hypertension

   • Alexander Logan

   Clinical Trials Report Pages: 121 - 123

10. Is angiotensin II made inside or outside of the cell?

    • Wenxia Chai
    • A. H. Jan Danser

    OriginalPaper Pages: 124 - 127

11. Role of angiotensin III in hypertension

    • Annabelle Reaux-Le Goazigo
    • Xavier Iturrioz
    • Catherine Llorens-Cortes

    OriginalPaper Pages: 128 - 134

12. Molecular evidence of tissue renin-angiotensin systems: A focus on the brain

    • Koji Sakai
    • Curt D. Sigmund

    OriginalPaper Pages: 135 - 140

13. The salt paradox and its possible implications in managing hypertensive diabetic patients

    • Volker Vallon
    • Roland Blantz
    • Scott Thomson

    OriginalPaper Pages: 141 - 147

14. Cellular mechanisms and treatment of diabetes vascular complications converge on reactive oxygen species

    • Catharine I. Whiteside

    OriginalPaper Pages: 148 - 154